[1]丁艳霞,王 佳,司玉环,等.利水保肝巴布剂对肝腹水的药效评价[J].医学信息,2025,38(08):118-122.[doi:10.3969/j.issn.1006-1959.2025.08.024]
　DING Yanxia,WANG Jia,SI Yuhuan,et al.Pharmacodynamic Evaluation of Lishui Baogan Cataplasm on Hepatic Ascites[J].Journal of Medical Information,2025,38(08):118-122.[doi:10.3969/j.issn.1006-1959.2025.08.024]
点击复制

利水保肝巴布剂对肝腹水的药效评价()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年08期
页码:
118-122
栏目:
论著
出版日期:
2025-04-15

文章信息/Info

Title:
Pharmacodynamic Evaluation of Lishui Baogan Cataplasm on Hepatic Ascites
文章编号:
1006-1959（2025）08-0118-05
作者:
丁艳霞1; 王 佳1; 司玉环1; 杜雅情1; 余聪睿1; 刘 晨1; 魏倩囡2
1.河南大学药学院，河南 开封 475000；2.河南大学第一附属医院医学研究中心，河南 开封 475000
Author(s):
DING Yanxia1;  WANG Jia1;  SI Yuhuan1;  DU Yaqing1;  YU Congrui1;  LIU Chen1;  WEI Qiannan2
1.School of Pharmacy, Henan University, Kaifeng 475000, Henan, China;2.Medical Research Center, the First Affiliated Hospital of Henan University, Kaifeng 475000, Henan, China
关键词:
巴布剂; 肝腹水; 药效评价
Keywords:
Cataplasm;  Hepatic ascites;  Pharmacodynamic evaluation
分类号:
R285.5
DOI:
10.3969/j.issn.1006-1959.2025.08.024
文献标志码:
A
摘要:
目的 考察利水保肝巴布剂治疗肝腹水的疗效。方法 采用H22瘤细胞造小鼠肝腹水模型。造模1天后，空白组、模型组给予空白基质贴，阳性药组灌胃呋塞米混悬液[6 mg/（kg·d）]，巴布剂低、中、高剂量组分别给含生药剂量为0.15 g/（cm2·d），0.30 g/（cm2·d），0.60 g/（cm2·d），给药面积4 cm2，每天1次，连续给药10 d。称量小鼠的体质量，测量腹围，统计小鼠死亡数，记录小鼠尿量和腹水量；ELISA检测小鼠血清白蛋白（ALB）、总蛋白（TP）、谷草转氨酶（AST）、谷丙转氨酶（ALT）含量，HE染色观察小鼠肝组织的病变情况。结果 空白组小鼠健康状态良好，体重、腹围正常，无死亡现象。与空白组相比，模型组小鼠体重、腹围增加（P＜0.05）；与空白组比较，模型组小鼠死亡率升高，达54.54%；与空白组相比，模型组小鼠平均尿量减少（P＜0.01）；与模型组相比，阳性药组及巴布剂低、中、高剂量组尿量增多，巴布剂各剂量组小鼠血清AST、ALT含量降低，TP含量增加（P＜0.05）；HE染色肝脏切片显示，与模型组比较，巴布剂各剂量组肝损伤均有不同程度的减轻。结论 利水保肝巴布剂对肝腹水，具有明显的消腹水和保肝作用。
Abstract:
Objective To investigate the effect of Lishui Baogan cataplasm for the treatment of hepatic ascites. Methods The mouse model of hepatic ascites was established by H22 tumor cells. One day after modeling, the blank group and the model group were given blank matrix paste, the positive drug group was given furosemide suspension [6 mg/(kg·d)], and the low, medium and high dose groups of cataplasm were given crude drug doses of 0.15 g/(cm2·d), 0.30 g/(cm2·d), 0.60 g/(cm2·d), respectively, the administration area was 4 cm2, once a day for 10 days. The body weight of mice was weighed, the abdominal circumference was measured, the number of deaths in mice was counted, and the urine volume and ascites volume of mice were recorded. The contents of serum albumin (ALB), total protein (TP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in mice were detected by ELISA, and the pathological changes of liver tissue in mice were observed by HE staining. Results The mice in the black group were in good health with normal weight and abdominal circumference, and no signs of death. Compared with the black group, the weight and abdominal circumference of mice in the low, medium and high dose groups of cataplasm significantly increased (P<0.05). Compared with the blank group, the mortality rate of the model group was significantly increased, reaching 54.54%. Compared with the blank group, the average urine volume of mice in the model group decreased (P<0.01). Compared with the model group, the urine volume of the positive drug group and the low, medium and high dose groups of cataplasm increased, and the ascites of the positive drug group and the low, medium and high dose groups of cataplasm decreased to varying degrees, among which the ascites of the medium dose group decreased significantly (P<0.05). The serum AST and ALT levels of mice in each dose group of cataplasm were reduced, while the TP level was increased (P<0.05). HE staining sections of liver tissue showed that compared with the model group, liver injury in each dose group of cataplasm was alleviated to varying degrees. Conclusion Lishui Baogan cataplasm has obvious effect on ascites and liver protection.

参考文献/References:

[1]郦昱琨,尹文俊,安晓婕,等.肝腹水患者合用呋塞米与甘露醇致急性肾损伤风险因素分析及预测[J].中国医院药学杂志,2021,41(23):2478-2482.[2]Benmassaoud A,Freeman SC,Roccarina D,et al.Treatment for asci-tes in adults with decompensated liver cirrhosis:a network meta-analysis[J].Cochrane Database Syst Rev,2020,1(1):CD013123.[3]Garbuzenko DV,Arefyev NO.Current approaches to the management of patients with cirrhotic ascites[J].World J Gastroenterol,2019,25(28):3738-3752.[4]Runyon BA,AASLD Practice Guidelines Committee.Management of adult patients with ascites due to cirrhosis: an update[J].Hepatology,2009,49(6):2087-2107.[5]姚锦慧.利尿剂呋塞米与多巴胺联合治疗肝腹水的临床体会[J].智慧健康,2019,5(32):88-89.[6]易艳容,申月明,王赛,等.经颈静脉肝内门体分流术治疗乙型肝炎肝硬化合并或不合并门静脉血栓形成的比较[J].肝脏,2023,28(4):448-451.[7]孙静,张伟伟,马智勇,等.经颈静脉肝内门体分流术联合胃冠状静脉栓塞术治疗乙型肝炎肝硬化并发食管胃静脉曲张患者效果分析[J].实用肝脏病杂志,2022,25(6):853-856.[8]王乡,陈积,唐茂华.复方肝荣汤辅助抗病毒治疗对慢性乙型肝炎免疫球蛋白及肝功能效果评价[J].中华中医药学刊,2021,39(7):85-88.[9]田孝锋,郑建军.益气活血利水方治疗肝硬化腹水的临床观察[J].陕西中医,2016,37(8):1049-1051.[10]李寿杰.逐水膏外敷中极穴治疗脾肾阳虚型恶性腹水临床疗效观察[J].实用中西医结合临床,2015,15(12):25-27.[11]薛柯.利水保肝巴布剂的制备及其功效评价[D].郑州:河南大学,2022. [12]李瑛,胡振斌,徐昆,等.中医药治疗肝硬化腹水临床研究概述[J].中西医结合肝病杂志,2022,32(2):185-188.[13]顾欢,芦龙青,朱英.肝硬化腹腔积液的中医药治疗现状[J].辽宁中医杂志,2020,47(4):211-214.[14]汪廉营,蔡怡航,张均倡.从“衰其大半而止”谈臌胀证治[J].中医学报,2021,36(6):1195-1198.[15]陆亚明.肝硬化腹水的辨证施治[J].中国医药导报,2008,5(13):74-75.[16]王飞,陈宝根.鳖甲煎丸治疗肝纤维化[J].中医学报,2024,39(2):437-439.[17]刘德福.托伐普坦联合养阴利水散结法治疗肝硬化顽固性腹水的效果分析[J].中国疗养医学,2021,30(9):976-980.[18]佘朋桂,谭小雯,郭红玲.杠板归总黄酮提取物对肝硬化腹腔积液大鼠肝功能及水通道蛋白的影响[J].临床合理用药,2023,16(12):84-87.[19]潘永福,许钒,王成业,等.基于水通道蛋白研究当归芍药散对肝硬化腹水大鼠的干预作用[J].中国实验方剂学杂志,2015,21(8):111-115.[20]代莹,邓炯,陆逸君,等.黄杞苷下调PERK-ATF4信号通路改善肝硬化大鼠肝脏的作用[J].河北医学,2023,29(5):737-742.

相似文献/References:

[1]许弄章,陈 璐,王翠红,等.大黄祛伤巴布剂的制备工艺研究[J].医学信息,2022,35(19):78.[doi:10.3969/j.issn.1006-1959.2022.19.021]
　XU Nong-zhang,CHEN Lu,WANG Cui-hong,et al.Preparation Technology of Dahuang Qushang Cataplasm[J].Journal of Medical Information,2022,35(08):78.[doi:10.3969/j.issn.1006-1959.2022.19.021]

更新日期/Last Update: 1900-01-01